The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.

Oxford regenerative medicine spinout OxStem, which raised $24.4m in 2016, has launched two subsidiaries to focus on therapies for diabetes, chronic inflammation and wound healing.

Ginkgo Bioworks participated in the round in addition to expanding an existing strategic partnership with bioprocessing technology developer Genomatica.

Anju Software has paid an undisclosed sum to acquire healthcare data provider Zephyr Health, which had raised $33.5m from investors including GV.

Peptide-based drug developer Navigen has been backed by University of Utah-based student venturing fund UVF II in its first equity round.

The SoftBank-backed precision oncology test developer floated above its range and saw its share price rise 69% on the first day of trading.

KIT-founded valve actuator manufacturer Memetis has received capital from the university and HTGF to help expand development and production.

Five US-based biomedical projects at Wayne State University have received Mtrac funding to pursue goals including better immunotherapy and new antibiotics.

Cellular therapy developer Gamida Cell, which counts Novartis as its largest investor, has filed for a $69m initial public offering.

The nine-figure renminbi sum follows a series A round of undisclosed size two years ago that was backed by THG Ventures.